Kiniksa Pharmaceuticals Stock Investor Sentiment
| KNSA Stock | USD 23.81 0.73 3.16% |
About 69 percent of all Kiniksa Pharmaceuticals' investors are curious in acquiring. The analysis of the overall investor sentiment regarding Kiniksa Pharmaceuticals suggests that a large number of traders are confidant. The current market sentiment, together with Kiniksa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Kiniksa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Kiniksa |
Kiniksa Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Kiniksa Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Kiniksa Pharmaceuticals that are available to investors today. That information is available publicly through Kiniksa media outlets and privately through word of mouth or via Kiniksa internal channels. However, regardless of the origin, that massive amount of Kiniksa data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Kiniksa Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Kiniksa Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Kiniksa Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Kiniksa Pharmaceuticals alpha.
Kiniksa Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 1750 shares by Ragosa Mark of Kiniksa Pharmaceuticals subject to Rule 16b-3 | 01/07/2025 |
2 | Disposition of 12323 shares by Eben Tessari of Kiniksa Pharmaceuticals at 18.13 subject to Rule 16b-3 | 01/15/2025 |
3 | Acquisition by Baker Bros. Advisors Lp of 4730 shares of Kiniksa Pharmaceuticals subject to Rule 16b-3 | 01/27/2025 |
4 | Disposition of 7000 shares by Eben Tessari of Kiniksa Pharmaceuticals at 3.8 subject to Rule 16b-3 | 02/10/2025 |
5 | Disposition of 14000 shares by Eben Tessari of Kiniksa Pharmaceuticals at 19.57 subject to Rule 16b-3 | 02/12/2025 |
6 | Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy | 02/25/2025 |
7 | Kiniksa Pharmaceuticals Outperform Rating Reiterated at Wedbush | 02/28/2025 |
8 | Wall Street Analysts See a 73.42 percent Upside in Kiniksa Pharmaceuticals Can the Stock Really Move This High | 03/03/2025 |
9 | Is Kiniksa Pharmaceuticals International, plc the Best UK Growth Stock to Buy Now | 03/06/2025 |
10 | Disposition of 36372 shares by Ragosa Mark of Kiniksa Pharmaceuticals at 22.25 subject to Rule 16b-3 | 03/12/2025 |
11 | 3 No-Brainer Healthcare Stocks to Buy With 1,000 Right Now | 03/14/2025 |
12 | Disposition of 11464 shares by Ragosa Mark of Kiniksa Pharmaceuticals at 12.97 subject to Rule 16b-3 | 03/17/2025 |
Complementary Tools for Kiniksa Stock analysis
When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |